We all know the sci-fi classics, but many great titles slip into obscurity and are still worth watching, even decades after ...

Biotechnology company Pandorum Technologies has raised $18 million in a Series B funding round to advance and market tissue regenerative therapies. Pandorum specialises in programmable regenerative ...

QuantX will deploy Series B proceeds toward IND-enabling advancement of oral STAT6 and IL-17 inhibitors in immunology/inflammation and continued discovery expansion on its computational platform.

BENGALURU, India & SAN CARLOS, Calif. Pandorum Technologies, a biotechnology company pioneering programmable regenerative medicine, with operations in India and the United States, has announced the ...

Pandorum Technologies, a biotechnology company pioneering programmable regenerative medicine, with operations in India and the United States, has announced the closing of a US$ 18 million in Series B ...

Pandorum Technologies has raised $18 million in a Series B funding round to advance clinical development and expand market access for its regenerative therapies. The India and US-based biotechnology ...

Funding accelerates clinical development and market access across the U.S., Asia, and the Middle East Pandorum Technologies, a biotechnology company pioneering programmable regenerative medicine, with ...

BENGALURU, India & SAN CARLOS, Calif., February 09, 2026--(BUSINESS WIRE)--Pandorum Technologies, a biotechnology company pioneering programmable regenerative medicine, with operations in India and ...

Pandorum Technologies, a biotechnology company focused on programmable regenerative medicine, has raised $18 million in a Series B funding round to advance clinical development and expand global ...

Biotechnology firm Pandorum Technologies has raised $18 million (Rs 163 crore) in a Series B round to advance the clinical development of its therapies that target diseases on the surface of the eye.